- Details
- Piet Ost discusses the treatment of oligorecurrent prostate cancer after local therapy at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Currently, there is no consensus definition for oligometastatic disease although a consensus working definition is being developed by the EORTC-ESTRO group. Highlighting findings from his own trial, Dr. Ost also frames these two main points durin...
|
- Details
- Michael Morris presented de novo oligometastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019) during the session on PSA Recurrence After Radical Local Therapy and Oligometastatic Prostate Cancer. His presentation highlights trials that support level 1 evidence that AR-directed therapy improves overall survival in M1 disease, trials that have assessed metastasis...
|
- Details
- Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials. In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring C...
|
- Details
- Stefano Fanti presents his point of view on the future of prostate cancer imaging at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately. Dr. Fanti believes that th...
|
- Details
- Eleni Efstathiou presents an overview of neuroendocrine prostate cancer during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Efstathiou touches on the inaccuracies in the terminology of neuroendocrine prostate cancer, the current state of aggressive variant prostate cancer, where efforts are in place to...
|
- Details
- Charles Drake presented on immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) during the Management of Castration-resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He reviews several immunotherapy trials including the first major successful trial in immunotherapy for prostate cancer, the IMPACT trial in 2010 which led...
|
- Details
- Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...
|
- Details
- Christopher Sweeney presents on systemic therapy for prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). The spectrum of patients starting androgen deprivation therapy (ADT) for metastatic disease is quite vast. Discussing several treatments and several studies as well as their overall survival treatment benefit Dr. Sweeney focuses on which systemic therapy for which...
|
- Details
- The aim of this presentation by Gerhardt (Gert) Attard at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 was to provide the research community with the information required to make the right choice on the dose and regimen of prednisone to combine with abiraterone and indications for combining dexamethasone with abiraterone, how to maximize therapy of steroids with abiraterone aceta...
|
- Details
- Eli Van Allen shares details on The Metastatic Prostate Cancer Project, a project part of a larger nationwide genomic research project called "Count Me In" for men with advanced or metastatic prostate cancer. The Metastatic Prostate Cancer Project takes a new approach to cancer research in which researchers partner directly with men with metastatic and/or advanced prostate cancer, who share their...
|
